Ultrasound contrast developer Sonus Pharmaceuticals of Bothell, WA, has named Michael Martino as president and COO. Martino will assume day-to-day operational responsibilities formerly held by Sonus founder Dr. Steven Quay, who will remain CEO of the
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell, WA, has named Michael Martino as president and COO. Martino will assume day-to-day operational responsibilities formerly held by Sonus founder Dr. Steven Quay, who will remain CEO of the company and will add chairman to his title. Martino comes to Sonus from the nuclear medicine division of Mallinckrodt of St. Louis, which has a product marketing alliance with Sonus rival Molecular Biosystems.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.